Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma.

Paillard C, Salmon A, Curtillet C, David A, Halle P, Cachin F, Bordigoni P, Michel G, Rousseau R, Dore E, Isfan F, Merlin E, Rochette E, Demeocq F, Kanold J.

Pediatr Transplant. 2010 Feb;14(1):109-14. doi: 10.1111/j.1399-3046.2009.01140.x. Epub 2009 Mar 11.

PMID:
19490483
2.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
3.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.

Biol Blood Marrow Transplant. 2001;7(4):230-8.

5.

Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.

Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, Banna G, Tirelli U, Soligo D, Santoro A.

Eur J Haematol. 2007 Apr;78(4):322-9. Epub 2007 Jan 23.

PMID:
17253967
6.

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group.

J Clin Oncol. 2003 Jul 15;21(14):2747-53.

PMID:
12860954
7.

Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.

Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR.

Cancer. 2002 May 1;94(9):2409-15.

8.

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.

Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J.

Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83.

10.

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Haematologica. 2007 May;92(5):627-34.

11.

Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.

Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L.

Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9.

12.

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group.

Ann Hematol. 2003 Jun;82(6):336-42. Epub 2003 May 1.

PMID:
12728337
13.

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.

Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE.

Bone Marrow Transplant. 2000 Sep;26(6):615-20.

14.

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.

Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G.

Exp Hematol. 2003 Jan;31(1):73-80.

PMID:
12543109
15.

Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.

Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, Florio G, Lercari G, Valbonesi M, Casarino L, De Stefano F, Geniram A, Venturino M, Tedeschi L, Palmieri G, Piaggio G, Podestà M, Frassoni F, Van Lint MT, Marmont AM, Bacigalupo A.

Haematologica. 1998 Oct;83(10):904-9.

16.

Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria.

Lee JL, Lee JH, Lee JH, Choi SJ, Kim S, Seol M, Lee YS, Chi HS, Park CJ, Kim WK, Lee JS, Lee KH.

Eur J Haematol. 2003 Aug;71(2):114-8.

PMID:
12890150
17.

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS.

Biol Blood Marrow Transplant. 2002;8(9):468-76.

18.

Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.

Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S.

Clin Cancer Res. 2002 Apr;8(4):1014-20.

19.

Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.

Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR.

Biol Blood Marrow Transplant. 2001;7(11):604-12.

20.

Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.

Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y.

Am J Hematol. 2007 Oct;82(10):873-80.

Supplemental Content

Support Center